Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Phase 3positiveBemnifosbuvir/RuzasvirSofosbuvir/VelpatasvirPositive
AI Analysis
Summary
Atea Pharmaceuticals announced that bemnifosbuvir/ruzasvir met its primary and secondary endpoints in the Phase 3 C-BEYOND North America trial, demonstrating non-inferiority to the standard-of-care sofosbuvir/velpatasvir in treating hepatitis C virus.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Met both primary and secondary endpoints; achieved non-inferiority compared to sofosbuvir/velpatasvir
Importance:8/10
Sentiment:
0.85
Phase 3 datahepatitis Cnon-inferiority trialhead-to-head comparison
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 28, 2026 11:00 AM